Financials BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:01:04 2024-05-17 am EDT			5-day change	1st Jan Change
0.572 ^EUR	-4.67%		+4.00%	-47.04%

May. 15	BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	CI
May. 02	Benevolentai S.A. Announces Directorate Changes	CI

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	363.4	110	59.68	-	-
Enterprise Value (EV) ¹	233.2	37.11	29.08	3.291	-85.33
P/E ratio	-2.06 x	-1.75 x	-9.88 x	-7.59 x	-6.92 x
Yield	-	-	-	-	-
Capitalization / Revenue	34.4 x	15 x	1.78 x	1.91 x	2.66 x
EV / Revenue	22.1 x	5.06 x	0.86 x	0.11 x	-3.8 x
EV / EBITDA	-2.55 x	-0.5 x	-0.99 x	-0.09 x	2.04 x
EV / FCF	-2.99 x	-0.64 x	-0.9 x	-0.12 x	-
FCF Yield	-33.5%	-157%	-112%	-856%	-
Price to Book	2.19 x	1.24 x	1.03 x	2.24 x	-
Nbr of stocks (in thousands)	117,489	117,489	121,940	-	-
Reference price ²	3.093	0.9364	0.4894	0.4894	0.4894
Announcement Date	3/16/23	3/14/24	-	-	-

¹GBP in Million²GBP

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net sales ¹	4.625	10.56	7.331	33.62	31.32	22.46
EBITDA ¹	-	-91.54	-74.69	-29.51	-34.79	-41.86
EBIT ¹	-	-197	-77.57	-31.4	-36.6	-42.44
Operating Margin	-	-1,865.85%	-1,058.15%	-93.38%	-116.86%	-188.94%
Earnings before Tax (EBT) ¹	-	-	-72.65	-35.04	-49.22	-40.12
Net income ¹	-86.48	-163.9	-63.32	-8.082	-14.06	-27.79
Net margin	-1,869.92%	-1,552.35%	-863.69%	-24.04%	-44.9%	-123.72%
EPS ²	-	-1.502	-0.5350	-0.0496	-0.0644	-0.0707
Free Cash Flow ¹	-	-78.07	-58.23	-32.45	-28.19	-
FCF margin	-	-739.29%	-794.28%	-96.52%	-89.98%	-
FCF Conversion (EBITDA)	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-
Announcement Date	3/15/22	3/16/23	3/14/24	-	-	-

¹GBP in Million²GBP

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S2	2023 S1	2023 S2	2024 S1	2024 S2
Net sales ¹	5.717	5.297	2.034	8	56
EBITDA	41.5	-	-	-	-
EBIT ¹	-62.49	-40.56	-31.72	-26.86	20.7
Operating Margin	-1,093%	-765.72%	-1,559.64%	-335.8%	36.96%
Earnings before Tax (EBT)	-	-	-	-	-
Net income	-	-	-	-	-
Net margin	-	-	-	-	-
EPS	-	-0.3120	-0.2230	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	3/16/23	9/21/23	3/14/24	-	-

¹GBP in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-
Net Cash position ¹	-	130	72.9	30.6	56.4	145
Leverage (Debt/EBITDA)	-	-	-	-	-	-
Free Cash Flow ¹	-	-78.1	-58.2	-32.4	-28.2	-
ROE (net income / shareholders' equity)	-	-73.7%	-51%	-23.6%	-12.7%	-
ROA (Net income/ Total Assets)	-	-56.9%	-	-	-	-
Assets ¹	-	288.3	-	-	-	-
Book Value Per Share ²	-	1.410	0.7600	0.4800	0.2200	-
Cash Flow per Share	-	-	-	-	-	-
Capex ¹	-	1.16	1.11	2	2	-
Capex / Sales	-	10.97%	15.07%	5.95%	6.39%	-
Announcement Date	3/15/22	3/16/23	3/14/24	-	-	-

¹GBP in Million²GBP

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for BenevolentAI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4894 GBP

Average target price

1.632 GBP

Spread / Average Target

+233.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-47.04%	75.83M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research